These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23738746)

  • 1. The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab.
    van Mierlo GJ; Cnubben NH; Wouters D; Wolbink GJ; Hart MH; Rispens T; Ganderup NC; Kuper CF; Aarden L; Penninks AH
    J Immunotoxicol; 2014; 11(1):62-71. PubMed ID: 23738746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Göttingen minipig® as an alternative non-rodent species for immunogenicity testing: a demonstrator study using the IL-1 receptor antagonist anakinra.
    van Mierlo GJ; Cnubben NH; Kuper CF; Wolthoorn J; van Meeteren-Kreikamp AP; Nagtegaal MM; Doornbos R; Ganderup NC; Penninks AH
    J Immunotoxicol; 2013; 10(1):96-105. PubMed ID: 23134195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
    Radstake TR; Svenson M; Eijsbouts AM; van den Hoogen FH; Enevold C; van Riel PL; Bendtzen K
    Ann Rheum Dis; 2009 Nov; 68(11):1739-45. PubMed ID: 19019895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
    Ben-Horin S; Mazor Y; Yanai H; Ron Y; Kopylov U; Yavzori M; Picard O; Fudim E; Maor Y; Lahat A; Coscas D; Eliakim R; Dotan I; Chowers Y
    Aliment Pharmacol Ther; 2012 Mar; 35(6):714-22. PubMed ID: 22288419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
    Papadakis KA; Shaye OA; Vasiliauskas EA; Ippoliti A; Dubinsky MC; Birt J; Paavola J; Lee SK; Price J; Targan SR; Abreu MT
    Am J Gastroenterol; 2005 Jan; 100(1):75-9. PubMed ID: 15654784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis.
    Takahashi H; Tsuji H; Ishida-Yamamoto A; Iizuka H
    J Dermatol; 2013 Jan; 40(1):39-42. PubMed ID: 23039179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
    West RL; Zelinkova Z; Wolbink GJ; Kuipers EJ; Stokkers PC; van der Woude CJ
    Aliment Pharmacol Ther; 2008 Nov; 28(9):1122-6. PubMed ID: 18691349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
    Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
    Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
    Palframan R; Airey M; Moore A; Vugler A; Nesbitt A
    J Immunol Methods; 2009 Aug; 348(1-2):36-41. PubMed ID: 19567252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.
    Zheng Y; Tesar DB; Benincosa L; Birnböck H; Boswell CA; Bumbaca D; Cowan KJ; Danilenko DM; Daugherty AL; Fielder PJ; Grimm HP; Joshi A; Justies N; Kolaitis G; Lewin-Koh N; Li J; McVay S; O'Mahony J; Otteneder M; Pantze M; Putnam WS; Qiu ZJ; Ruppel J; Singer T; Stauch O; Theil FP; Visich J; Yang J; Ying Y; Khawli LA; Richter WF
    MAbs; 2012; 4(2):243-55. PubMed ID: 22453096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.